HK1212033A1 - Antibodies to olanzapine and use thereof - Google Patents

Antibodies to olanzapine and use thereof

Info

Publication number
HK1212033A1
HK1212033A1 HK15112819.7A HK15112819A HK1212033A1 HK 1212033 A1 HK1212033 A1 HK 1212033A1 HK 15112819 A HK15112819 A HK 15112819A HK 1212033 A1 HK1212033 A1 HK 1212033A1
Authority
HK
Hong Kong
Prior art keywords
olanzapine
antibodies
Prior art date
Application number
HK15112819.7A
Other languages
English (en)
Chinese (zh)
Inventor
Eric Hryhorenko
Banumathi Sankaran
Thomas R Decory
Theresa Tubbs
Linda Colt
Bart M Remmerie
Rhys Salter
Matthew Garrett Donahue
Yong Gong
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of HK1212033A1 publication Critical patent/HK1212033A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15112819.7A 2012-08-21 2015-12-30 Antibodies to olanzapine and use thereof HK1212033A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691645P 2012-08-21 2012-08-21
PCT/US2013/055826 WO2014031662A2 (en) 2012-08-21 2013-08-20 Antibodies to olanzapine and use thereof

Publications (1)

Publication Number Publication Date
HK1212033A1 true HK1212033A1 (en) 2016-06-03

Family

ID=50148311

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112819.7A HK1212033A1 (en) 2012-08-21 2015-12-30 Antibodies to olanzapine and use thereof

Country Status (11)

Country Link
US (3) US9494608B2 (fi)
EP (1) EP2888590B1 (fi)
JP (3) JP6216926B2 (fi)
CN (2) CN107253993B (fi)
AU (3) AU2013305901B2 (fi)
CA (1) CA2882596C (fi)
ES (1) ES2807902T3 (fi)
HK (1) HK1212033A1 (fi)
PL (1) PL2888590T3 (fi)
PT (1) PT2888590T (fi)
WO (1) WO2014031662A2 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013305884B2 (en) 2012-08-21 2017-10-05 Saladax Biomedical Inc. Antibodies to risperidone haptens and use thereof
CA2882594C (en) 2012-08-21 2019-07-16 Ortho-Clinical Diagnostics, Inc. Antibodies to risperidone and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
CA2882492C (en) 2012-08-21 2019-05-28 Ortho-Clinical Diagnostics, Inc. Antibodies to aripiprazole haptens and use thereof
PL3385284T3 (pl) 2012-08-21 2020-09-21 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
WO2014031603A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone haptens and use thereof
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10145855B2 (en) * 2016-05-03 2018-12-04 Synapse Biosciences, LLC Methods and dose packs for monitoring medication adherence

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
EP0560411B1 (en) 1987-04-27 2000-07-26 Unilever N.V. Specific binding assays
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
AU1331892A (en) 1991-02-01 1992-09-07 Coulter Corporation Method of producing f(ab')2 fragments of immunoglobulins
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
TW268005B (fi) 1992-05-29 1996-01-11 Lilly Industries Ltd
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
AU710106B2 (en) 1994-06-10 1999-09-16 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
JP2005526044A (ja) 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
EP1492794B1 (en) 2002-03-28 2007-12-12 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
WO2004011031A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
DE60313634T2 (de) 2002-08-05 2008-01-31 Eli Lilly And Co., Indianapolis Piperazinsubstituierte arylbenzodiazepine
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
JP2007505864A (ja) 2003-09-23 2007-03-15 フェルミオン オサケ ユキチュア クエチアピンの製造
JP4976134B2 (ja) 2003-10-01 2012-07-18 アドラー コーポレーション スピロ環複素環誘導体及びそれらを使用する方法
WO2005059547A2 (en) 2003-12-12 2005-06-30 Inverness Medical Switzerland Gmbh Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP2010507648A (ja) * 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
KR20100075455A (ko) 2007-09-27 2010-07-02 노파르티스 아게 약물 모니터링 분석법
KR20100107466A (ko) * 2007-12-13 2010-10-05 세키스이 메디칼 가부시키가이샤 항 오플록사신 모노클로날 항체, 이것을 이용한 오플록사신의 면역학적 측정 방법
MX2011000875A (es) 2008-07-21 2011-04-05 Probiodrug Ag Ensayo de anticuerpo de diagnostico.
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EA201100613A1 (ru) 2008-10-14 2011-12-30 Астразенека Аб Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
EP2347015A4 (en) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
WO2010083843A1 (en) 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
CA2777807A1 (en) 2009-10-16 2011-04-21 Amic Ab An assay method and devices involving the use of magnetic particles
EP2325322A1 (en) * 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
US20110183963A1 (en) 2009-12-31 2011-07-28 Travis Mickle Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same
PL2544536T3 (pl) 2010-03-11 2019-05-31 Kempharm Inc Koniugaty kwasów tłuszczowych z kwetiapiną, sposób ich wytwarzania i stosowania
US8114621B2 (en) * 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102276592B (zh) * 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
CN102276624B (zh) * 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2014028800A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
ES2971506T3 (es) 2012-08-21 2024-06-05 Janssen Pharmaceutica Nv Haptenos de paliperidona
AU2013305884B2 (en) 2012-08-21 2017-10-05 Saladax Biomedical Inc. Antibodies to risperidone haptens and use thereof
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
CA2882492C (en) 2012-08-21 2019-05-28 Ortho-Clinical Diagnostics, Inc. Antibodies to aripiprazole haptens and use thereof
PL3385284T3 (pl) 2012-08-21 2020-09-21 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PT2888257T (pt) 2012-08-21 2017-11-14 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
WO2014031603A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone haptens and use thereof
TR201809424T4 (tr) 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
EP3492473A1 (en) * 2012-08-21 2019-06-05 Janssen Pharmaceutica NV Haptens of olanzipine
CA2882594C (en) 2012-08-21 2019-07-16 Ortho-Clinical Diagnostics, Inc. Antibodies to risperidone and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
EP2888590B1 (en) 2020-07-08
US9494608B2 (en) 2016-11-15
AU2013305901B2 (en) 2017-10-26
AU2013305901A1 (en) 2015-03-05
JP2018039787A (ja) 2018-03-15
US20190315885A1 (en) 2019-10-17
CN107253993B (zh) 2021-10-22
US20140057304A1 (en) 2014-02-27
US20170037152A1 (en) 2017-02-09
AU2019283820A1 (en) 2020-01-16
ES2807902T3 (es) 2021-02-24
EP2888590A2 (en) 2015-07-01
AU2019283820B2 (en) 2022-04-07
AU2018200541B2 (en) 2019-09-26
JP6442008B2 (ja) 2018-12-19
AU2018200541A1 (en) 2018-02-15
JP2019104725A (ja) 2019-06-27
CN107253993A (zh) 2017-10-17
PT2888590T (pt) 2020-09-11
WO2014031662A2 (en) 2014-02-27
PL2888590T3 (pl) 2020-11-30
CN104755928A (zh) 2015-07-01
JP6216926B2 (ja) 2017-10-25
EP2888590A4 (en) 2016-04-13
CN104755928B (zh) 2017-05-10
US10344098B2 (en) 2019-07-09
JP2015529202A (ja) 2015-10-05
CA2882596C (en) 2019-05-14
US11046786B2 (en) 2021-06-29
CA2882596A1 (en) 2014-02-27
WO2014031662A3 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
HK1255219A1 (zh) 喹硫平的抗體及其用途
HK1212034A1 (en) Antibodies to risperidone and use thereof
HK1212033A1 (en) Antibodies to olanzapine and use thereof
HK1211857A1 (en) Antibodies to olanzapine haptens and use thereof
HK1211957A1 (en) Antibodies to risperidone haptens and use thereof
HK1211959A1 (en) Antibodies to quetiapine haptens and use thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1211958A1 (en) Antibodies to paliperidone and use thereof
HK1260330A1 (zh) 阿立哌唑的抗體及其用途
GB201208372D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF THE APPLICANT FROM JANSSEN PHARMACEUTICA

Effective date: 20190916